Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514327955> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2514327955 abstract "Purpose/Background: Anticoagulation with Vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) is recommended for patients with atrial fibrillation (AF) and additional risk factors for stroke, regardless of the pattern of AF. Using an inception cohort design, GLORIA-AF collected data on antithrombotic therapy choices for patients with newly identified AF at risk of stroke in the course of routine care.Methods: Phase II began after the first NOAC became available for stroke prevention in AF and baseline data were recorded from November 2011 through December 2014 in 44 countries worldwide. To reduce selection bias, patients were recruited consecutively, irrespective of antithrombotic therapy received. Antithrombotic treatment is presented in relation to CHA2DS2VASc scores and the pattern of AF.Results: In phase II of GLORIA-AF, 15,092 patients with a recent diagnosis of AF and CHA2DS2VASc scores ≥ 1 were enrolled. Median age was 71 years and 39.1% were ≥ 75 years old; 45.5% were female, 74.6% had a history of hypertension, 23.1% diabetes mellitus and 86.1% had CHA2DS2VASc scores ≥ 2. AF was classified as paroxysmal in 53.4% (n = 8052), persistent in 35.5% (n = 5362) and permanent in 11.1% (n = 1678) of patients. Relationships of initial antithrombotic therapy to AF pattern and stroke risk are shown in the figure below and further data on regional differences will be presented.Conclusion: Initial antithrombotic therapy diverged from guideline recommendations. Patients with paroxysmal AF were less often anticoagulated than those with persistent or permanent AF, and nearly 22% of patients with paroxysmal AF at high stroke risk were untreated, or given aspirin or other antiplatelet therapy alone. ![][1] [1]: /embed/graphic-1.gif" @default.
- W2514327955 created "2016-09-16" @default.
- W2514327955 creator A5011723711 @default.
- W2514327955 creator A5011823926 @default.
- W2514327955 creator A5026613773 @default.
- W2514327955 creator A5030121388 @default.
- W2514327955 creator A5033104412 @default.
- W2514327955 creator A5048097130 @default.
- W2514327955 creator A5059084305 @default.
- W2514327955 creator A5074005348 @default.
- W2514327955 creator A5075493226 @default.
- W2514327955 creator A5076105916 @default.
- W2514327955 creator A5077997134 @default.
- W2514327955 creator A5086040903 @default.
- W2514327955 date "2015-11-10" @default.
- W2514327955 modified "2023-10-16" @default.
- W2514327955 title "Abstract 13565: Patterns of Newly Detected Atrial Fibrillation and Antithrombotic Treatment in GLORIA-AF Phase II" @default.
- W2514327955 hasPublicationYear "2015" @default.
- W2514327955 type Work @default.
- W2514327955 sameAs 2514327955 @default.
- W2514327955 citedByCount "0" @default.
- W2514327955 crossrefType "journal-article" @default.
- W2514327955 hasAuthorship W2514327955A5011723711 @default.
- W2514327955 hasAuthorship W2514327955A5011823926 @default.
- W2514327955 hasAuthorship W2514327955A5026613773 @default.
- W2514327955 hasAuthorship W2514327955A5030121388 @default.
- W2514327955 hasAuthorship W2514327955A5033104412 @default.
- W2514327955 hasAuthorship W2514327955A5048097130 @default.
- W2514327955 hasAuthorship W2514327955A5059084305 @default.
- W2514327955 hasAuthorship W2514327955A5074005348 @default.
- W2514327955 hasAuthorship W2514327955A5075493226 @default.
- W2514327955 hasAuthorship W2514327955A5076105916 @default.
- W2514327955 hasAuthorship W2514327955A5077997134 @default.
- W2514327955 hasAuthorship W2514327955A5086040903 @default.
- W2514327955 hasConcept C126322002 @default.
- W2514327955 hasConcept C127413603 @default.
- W2514327955 hasConcept C134018914 @default.
- W2514327955 hasConcept C142724271 @default.
- W2514327955 hasConcept C164705383 @default.
- W2514327955 hasConcept C187212893 @default.
- W2514327955 hasConcept C2776301958 @default.
- W2514327955 hasConcept C2777015399 @default.
- W2514327955 hasConcept C2779161974 @default.
- W2514327955 hasConcept C2780182762 @default.
- W2514327955 hasConcept C2780645631 @default.
- W2514327955 hasConcept C555293320 @default.
- W2514327955 hasConcept C71924100 @default.
- W2514327955 hasConcept C72563966 @default.
- W2514327955 hasConcept C78519656 @default.
- W2514327955 hasConceptScore W2514327955C126322002 @default.
- W2514327955 hasConceptScore W2514327955C127413603 @default.
- W2514327955 hasConceptScore W2514327955C134018914 @default.
- W2514327955 hasConceptScore W2514327955C142724271 @default.
- W2514327955 hasConceptScore W2514327955C164705383 @default.
- W2514327955 hasConceptScore W2514327955C187212893 @default.
- W2514327955 hasConceptScore W2514327955C2776301958 @default.
- W2514327955 hasConceptScore W2514327955C2777015399 @default.
- W2514327955 hasConceptScore W2514327955C2779161974 @default.
- W2514327955 hasConceptScore W2514327955C2780182762 @default.
- W2514327955 hasConceptScore W2514327955C2780645631 @default.
- W2514327955 hasConceptScore W2514327955C555293320 @default.
- W2514327955 hasConceptScore W2514327955C71924100 @default.
- W2514327955 hasConceptScore W2514327955C72563966 @default.
- W2514327955 hasConceptScore W2514327955C78519656 @default.
- W2514327955 hasOpenAccess W2514327955 @default.
- W2514327955 hasRelatedWork W1422496566 @default.
- W2514327955 hasRelatedWork W1977276852 @default.
- W2514327955 hasRelatedWork W2026073888 @default.
- W2514327955 hasRelatedWork W2279028468 @default.
- W2514327955 hasRelatedWork W2471432593 @default.
- W2514327955 hasRelatedWork W2472261290 @default.
- W2514327955 hasRelatedWork W2595654942 @default.
- W2514327955 hasRelatedWork W2604378539 @default.
- W2514327955 hasRelatedWork W2607469620 @default.
- W2514327955 hasRelatedWork W2792765218 @default.
- W2514327955 hasRelatedWork W2910168497 @default.
- W2514327955 hasRelatedWork W2918425589 @default.
- W2514327955 hasRelatedWork W2918849036 @default.
- W2514327955 hasRelatedWork W2938786224 @default.
- W2514327955 hasRelatedWork W2942601550 @default.
- W2514327955 hasRelatedWork W2959217544 @default.
- W2514327955 hasRelatedWork W2981847567 @default.
- W2514327955 hasRelatedWork W3001153022 @default.
- W2514327955 hasRelatedWork W3021554405 @default.
- W2514327955 hasRelatedWork W3180382634 @default.
- W2514327955 hasVolume "132" @default.
- W2514327955 isParatext "false" @default.
- W2514327955 isRetracted "false" @default.
- W2514327955 magId "2514327955" @default.
- W2514327955 workType "article" @default.
!["Purpose/Background: Anticoagulation with Vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) is recommended for patients with atrial fibrillation (AF) and additional risk factors for stroke, regardless of the pattern of AF. Using an inception cohort design, GLORIA-AF collected data on antithrombotic therapy choices for patients with newly identified AF at risk of stroke in the course of routine care.Methods: Phase II began after the first NOAC became available for stroke prevention in AF and baseline data were recorded from November 2011 through December 2014 in 44 countries worldwide. To reduce selection bias, patients were recruited consecutively, irrespective of antithrombotic therapy received. Antithrombotic treatment is presented in relation to CHA2DS2VASc scores and the pattern of AF.Results: In phase II of GLORIA-AF, 15,092 patients with a recent diagnosis of AF and CHA2DS2VASc scores ≥ 1 were enrolled. Median age was 71 years and 39.1% were ≥ 75 years old; 45.5% were female, 74.6% had a history of hypertension, 23.1% diabetes mellitus and 86.1% had CHA2DS2VASc scores ≥ 2. AF was classified as paroxysmal in 53.4% (n = 8052), persistent in 35.5% (n = 5362) and permanent in 11.1% (n = 1678) of patients. Relationships of initial antithrombotic therapy to AF pattern and stroke risk are shown in the figure below and further data on regional differences will be presented.Conclusion: Initial antithrombotic therapy diverged from guideline recommendations. Patients with paroxysmal AF were less often anticoagulated than those with persistent or permanent AF, and nearly 22% of patients with paroxysmal AF at high stroke risk were untreated, or given aspirin or other antiplatelet therapy alone. ![][1] [1]: /embed/graphic-1.gif"](?object=%22Purpose%2FBackground%3A%20Anticoagulation%20with%20Vitamin%20K%20antagonists%20(VKAs)%20or%20non-VKA%20oral%20anticoagulants%20(NOACs)%20is%20recommended%20for%20patients%20with%20atrial%20fibrillation%20(AF)%20and%20additional%20risk%20factors%20for%20stroke%2C%20regardless%20of%20the%20pattern%20of%20AF.%20Using%20an%20inception%20cohort%20design%2C%20GLORIA-AF%20collected%20data%20on%20antithrombotic%20therapy%20choices%20for%20patients%20with%20newly%20identified%20AF%20at%20risk%20of%20stroke%20in%20the%20course%20of%20routine%20care.Methods%3A%20Phase%20II%20began%20after%20the%20first%20NOAC%20became%20available%20for%20stroke%20prevention%20in%20AF%20and%20baseline%20data%20were%20recorded%20from%20November%202011%20through%20December%202014%20in%2044%20countries%20worldwide.%20To%20reduce%20selection%20bias%2C%20patients%20were%20recruited%20consecutively%2C%20irrespective%20of%20antithrombotic%20therapy%20received.%20Antithrombotic%20treatment%20is%20presented%20in%20relation%20to%20CHA2DS2VASc%20scores%20and%20the%20pattern%20of%20AF.Results%3A%20In%20phase%20II%20of%20GLORIA-AF%2C%2015%2C092%20patients%20with%20a%20recent%20diagnosis%20of%20AF%20and%20CHA2DS2VASc%20scores%20%E2%89%A5%201%20were%20enrolled.%20Median%20age%20was%2071%20years%20and%2039.1%25%20were%20%E2%89%A5%2075%20years%20old%3B%2045.5%25%20were%20female%2C%2074.6%25%20had%20a%20history%20of%20hypertension%2C%2023.1%25%20diabetes%20mellitus%20and%2086.1%25%20had%20CHA2DS2VASc%20scores%20%E2%89%A5%202.%20AF%20was%20classified%20as%20paroxysmal%20in%2053.4%25%20(n%20%3D%208052)%2C%20persistent%20in%2035.5%25%20(n%20%3D%205362)%20and%20permanent%20in%2011.1%25%20(n%20%3D%201678)%20of%20patients.%20Relationships%20of%20initial%20antithrombotic%20therapy%20to%20AF%20pattern%20and%20stroke%20risk%20are%20shown%20in%20the%20figure%20below%20and%20further%20data%20on%20regional%20differences%20will%20be%20presented.Conclusion%3A%20Initial%20antithrombotic%20therapy%20diverged%20from%20guideline%20recommendations.%20Patients%20with%20paroxysmal%20AF%20were%20less%20often%20anticoagulated%20than%20those%20with%20persistent%20or%20permanent%20AF%2C%20and%20nearly%2022%25%20of%20patients%20with%20paroxysmal%20AF%20at%20high%20stroke%20risk%20were%20untreated%2C%20or%20given%20aspirin%20or%20other%20antiplatelet%20therapy%20alone.%20!%5B%5D%5B1%5D%20%5B1%5D%3A%20%2Fembed%2Fgraphic-1.gif%22){kind=link}